This fund typically allocates a minimum of 80% of its capital to entities involved in the pharmaceutical sector, encompassing activities from scientific discovery and development to manufacturing and distribution of various medicinal products. Its holdings include both domestic and international companies, with the portfolio primarily consisting of common equities. Investment decisions are guided by a thorough fundamental analysis, assessing aspects like a company's financial health, its standing within the industry, and broader market and economic trends.
